CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


We found 7001 result(s)

Frequently Asked Questions: Expanding the CADTH Drug Review Process to Receive Patient Input Submissions From Individual Patients and Caregivers

Published on: October 5, 2015
Result type: General Content

Who is eligible under the newly expanded process to submit patient input to the CADTH pan-Canadian Oncology Drug Review (pCODR) program as an individual patient or caregiver? pCODR will accept patient input from individual patients and caregivers when there is no patient advocacy group representing patients with the particular tumour for w...

Dr. Luc Boileau

Published on: January 14, 2011
Result type: General Content

Member — Observer (Quebec) As a doctor trained at the Université de Sherbrooke and a specialist in public health, Dr. Luc Boileau holds a master’s in health administration from the Université de Montréal and a fellowship from the Canadian Health Services Research Foundation. In addition to his 25 years of clinical experience — particularly in...

ticagrelor (Brilinta)

Last Updated: October 10, 2018
Result type: Reports
Product Line: Common Drug Review
Generic Name: ticagrelor
Indications: Prevention of atherothrombotic events with history of myocardial infarction

  • Brand Name: Brilinta
  • Manufacturer: AstraZeneca Canada Inc
  • Project Number: SR0474-000
  • Project Status: Complete
  • Submission Type: New Indication